4 completed. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
Follow reloxaliase: new trials by email Literature Review of reloxaliase trials Research Report on reloxaliase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia ALLN-177 - Enteric Hyperoxaluria, Primary Hyperoxaluria | Phase 2 | Completed | Allena Pharmaceuticals | 15 | 2018-07-17 | 2020-12-30 |
| Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days ALLN-177, Placebo - Secondary Hyperoxaluria, Nephrolithiasis | Phase 2 | Completed | Allena Pharmaceuticals | 66 | 2015-09-01 | 2017-01-19 |
| Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones ALLN-177 low dose, ALLN-177 mid dose, ALLN-177 high dose - Secondary Hyperoxaluria, Nephrolithiasis | Phase 2 | Completed | Allena Pharmaceuticals | 32 | 2015-07-01 | 2018-01-11 |
| Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria ALLN-177 - Hyperoxaluria, Nephrolithiasis | Phase 2 | Completed | Allena Pharmaceuticals | 16 | 2014-09-01 | 2019-06-05 |
Kidney Calculi (4) · Hyperoxaluria (3) · Kidney Diseases (3) · Nephrolithiasis (3) · Urologic Diseases (3) · Hyperoxaluria, Primary (1)
United States (4) · Germany (1) · United Kingdom (1)
Annamaria Kausz, MD MS (2) · David Clark, MD (1) · Lee Brettman, MD, FACP (1)
2017 (1)